Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03954990|
Recruitment Status : Recruiting
First Posted : May 17, 2019
Last Update Posted : March 9, 2020
|Condition or disease||Intervention/treatment||Phase|
|Bacterial Vaginoses||Drug: Metronidazole Oral Drug: Placebo Oral Tablet||Phase 1|
The investigators are proposing a double-blinded, placebo controlled, randomized trial of 525 pregnant women undergoing induction or admitted in early labor and who are diagnosed with bacterial vaginosis. On admission to labor and delivery, patient will be counseled about the study. Patients who agree to be enrolled, will sign informed consent. Following enrollment patients will be screened for Bacterial vaginosis by doing a speculum exam and testing for Amsel's criteria. BV +ve patients will be randomized to receive either metronidazole 2 grams PO once or identically appearing placebo. The PI, study coordinator, or a collaborator will be responsible for the informed consent.
This will be a double-blinded randomized clinical trial. Neither the patient nor provider will be aware of treatment assignment. As with any other in-stance in which antibiotics are administered, there is a chance of an allergic or other adverse reaction. The patient will receive standard inpatient monitoring during the labor course and in the postpartum period, and so any immediate adverse reaction would be promptly detected.
Patient will be assessed intrapartum for development of chorioamninoitis. Postpartum patient will be assessed for infective complications up to 4 weeks. Neonates will be assessed for morbidities by chart review for 90 days.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||525 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Patient with bacterial vaginosis will be randomized to either treatment group to receive 2 g of metronidazole or control group to receive 2 g of placebo. Randomization to either control or treatment group will be done according to a randomization sequence that is computer generated and maintained by investigational drug pharmacy.|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Patients, providers, PI, investigators will be blinded.|
|Official Title:||Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity: A Randomized Controlled Trial|
|Actual Study Start Date :||October 11, 2019|
|Estimated Primary Completion Date :||June 1, 2021|
|Estimated Study Completion Date :||June 1, 2021|
Placebo Comparator: Control Arm
Placebo tablets oral, 4 tablets once.
Drug: Placebo Oral Tablet
Active Comparator: Treatment Arm
Will receive 4 tablets (2g) of metronidazole oral once.
Drug: Metronidazole Oral
4 tablets (2 g of metronidazole)
Other Name: Flagyl
- Rate of Composite outcome of maternal infections [ Time Frame: Labor to 4 weeks postpartum ]Including Chorioamnionitis, postpartum endometritis, wound infection, pelvic septic thrombosis, pelvic or abdominal abscess
- Rate of Chorioamnionitis [ Time Frame: From beginning of labor process until time of delivery ]Presumptive or confirmed diagnosis
- Rate of Postpartum Endometritis [ Time Frame: From time of delivery to 4 weeks postpartum ]Postpartum intrauterine infection
- Rate of Surgical Site Infection [ Time Frame: 4 weeks postpartum ]Including superficial or deep incisional surgical site infection
- Rate of Pelvic Septic Thrombosis [ Time Frame: 4 weeks postpartum ]Infection and thrombosis of pelvic vessels
- Rate of Pelvic abscess [ Time Frame: 4 weeks postpartum ]Detection of pelvic abscess on imaging
- Rate of Puerperal fever [ Time Frame: From beginning of labor process until time of delivery ]Temperature of ≥ 100.4 F at least twice 30 minutes apart or once ≥ 101F
- Rate of Maternal Death [ Time Frame: During labor and up to 4 weeks postpartum ]Death of mother while pregnant or within 28 days of pregnancy termination from any cause related to pregnancy or its management.
- Rate of additional postpartum procedures [ Time Frame: 4 weeks postpartum ]Additional imaging and invasive procedures to diagnose or treat postpartum infections
- Rate of Postpartum Antibiotics use [ Time Frame: 4 weeks postpartum ]Number of patients requiring antibiotics secondary to postpartum infections
- Rate of ER and unscheduled postpartum clinic visit [ Time Frame: 4 weeks postpartum ]Number of unscheduled clinic visits and ER visits secondary to infections.
- Number of days of hospital stay postpartum [ Time Frame: 4 weeks postpartum ]Number of days patients admitted to the hospital secondary to infections postpartum
- Rate of Adverse events [ Time Frame: 4 weeks postpartum ]Allergic reactions (anaphylaxis, angioedema, skin rashes including Stevens Johnson and Toxic Epidermal necrolysis), Gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation, ileus, etc)
- Rate of Confirmed neonatal sepsis [ Time Frame: 7 days of delivery ]Findings indicating positive cultures of blood, cerebrospinal fluid or urine obtained by catheterization or suprapubic aspiration, or cardiovascular collapse, or an unequivocal X-ray confirming infection in a clinically septic neonate.
- Rate of Suspected neonatal sepsis [ Time Frame: 7 days of delivery ]Presence of clinical signs/symptoms (hypothermia, fever, irritability, poor feeding, hypotonia, etc) causing the clinician to perform a sepsis work-up (blood, urine and/or cerebrospinal fluid, or chest X-ray), excludes routine work-up solely for positive maternal Group B Streptococcus (GBS) status.
- Rate of Neonatal morbidities [ Time Frame: 90 days after delivery ]Including Respiratory Distress syndrome(RDS), Necrotizing enterocolitis(NEC), Intraventricular hemorrhage (IVH), Bronchopulmonary Dysplasia (BPD)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03954990
|Contact: Mauricio La Rosa, MDfirstname.lastname@example.org|
|Contact: Mahmoud Abdelwahab, MDemail@example.com|
|United States, Texas|
|Universty of Texas Medical Branch||Recruiting|
|Galveston, Texas, United States, 77550|
|Contact: Mauricio La Rosa, MD 215-518-0694 firstname.lastname@example.org|
|Principal Investigator:||Mauricio La Rosa, MD||University of Texas medical branch, Galveston|